TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Profound Medical ( (TSE:PRN) ) has issued an announcement.
Profound Medical announced a significant milestone as The Hong Center Scottsdale, led by Dr. Y. Mark Hong, completed 200 independent TULSA Procedures for prostate disease. This achievement marks a new standard in MRI-guided prostate therapy, showcasing the potential of incision-free treatments to improve patient outcomes. Dr. Hong’s work highlights the capability of urologists to independently perform the TULSA Procedure, which is expected to transform prostate cancer treatment by offering a less invasive alternative to traditional surgery. The milestone underscores the growing adoption of Profound’s TULSA-PRO system, which provides precise, personalized therapy while preserving patients’ quality of life.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company is commercializing the TULSA-PRO system, which combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. This technology is aimed at providing a mainstream treatment modality for a wide range of prostate diseases.
Average Trading Volume: 19,833
Technical Sentiment Signal: Hold
Current Market Cap: C$284.4M
For detailed information about PRN stock, go to TipRanks’ Stock Analysis page.